respiratory papillomatosis

respiratory papillomatosis

Oncology A condition characterized by proliferation of benign papillomas in the respiratory tract, primarily the larynx, which may extend into airways and lungs Diagnosis Endoscopy Management Endoscopic excision, IFN alpha-n1, if refractory
References in periodicals archive ?
health agency also said two HPV types -- 16 and 18 -- cause 70 percent of cervical cancer and precancerous cervical lesions, while non-cancer causing types of HPV, especially types 6 and 11, can cause genital warts and respiratory papillomatosis.
INTRODUCTION OF A NATIONAL human pap illomavirus vaccination program in Australia has been associated with declines in the incidence of juvenile-onset recurrent respiratory papillomatosis, according to a nationwide study.
We conducted a retrospective study of the use of cidofovir and the measles, mumps, and rubella (MMR) vaccineas adjunctive treatments to lesion debridement in patients with recurrent respiratory papillomatosis (RRP).
Surgical treatment and adjuvant therapies of recurrent respiratory papillomatosis.
The foreign body bronchus was most popular indication for patient in our institute, among this the common foreign body was custard apple seed and aspiration of food particles in to the trachea, the next followed in our study was respiratory papillomatosis, treatment based on papilloma excision in order to keep the airway patent, however in some cases the disease is highly recurrent resulting in air way obstruction, and then tracheostomy is necessary.
Underbrink, "Recurrent Respiratory Papillomatosis," Otolaryngologic Clincs of North America 45, no.
Direct laryngoscopy and biopsy are essential to exclude other more common causes of vocal fold abnormalities, including malignancy and respiratory papillomatosis.
Anaconda Pharma's lead candidate is AP611074, a patented, direct-acting antiviral in development for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis, both of which are caused by human papillomavirus types 6 and 11.
Following closing, Biota acquires the AP611074, which is a patented, direct-acting antiviral in clinical development for the treatment of condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis (RRP), both of which are caused by human papillomavirus (HPV) types 6 and 11.
These low-risk HPV types are also the cause of recurrent respiratory papillomatosis, a condition that can be passed from mother to baby during the intrapartal period (Markowitz et al.
Anaconda is developing its lead product AP611074 to treat condyloma, also called anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis (RRP).
There she began her studies of human papillomaviruses and recurrent respiratory papillomatosis.